LENZ Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
About LENZ Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
LENZ Therapeutics is a commercial pharmaceutical company that develops and commercializes innovative therapies to improve vision. The company’s primary product is VIZZ (aceclidine ophthalmic solution 1.44%), a once-daily, pupil-selective prescription eye drop formulated to restore near vision for up to ten hours in adults experiencing presbyopia. Operating primarily in the self-pay pharmaceutical market, the company provides treatments for adult patients dealing with age-related near-vision loss. Its products reach consumers through retail pharmacies, e-pharmacy partners, and partnerships with eye care professionals including optometrists and ophthalmologists.
The company focuses its direct commercial operations within the United States, supported by a specialized sales force of over 100 individuals targeting approximately 15,000 eye care professionals. Internationally, the company establishes licensing and distribution partnerships across multiple territories, including Greater China, Canada, South Korea, Southeast Asia, and a nine-country region in the Middle East. The provided text does not state the location of the company's headquarters.
Summary of the business section of LENZ Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LENZ Therapeutics, Inc.
- Headquarters
- Solana Beach, CA
- Address
- 201 Lomas Santa Fe Drive, Suite 300 92075
- Phone
- (858) 925-7000
- Employees
- 152, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- LENZ
- Exchange
- Nasdaq
- IPO date
- Jun 28, 2021
- Shares outstanding
- 31M, Aug 5, 2026
- Public float
- $690.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-29 reverse, May 8, 2024; 1-for-7 reverse, Mar 22, 2024
- SEC CIK
- 1815776
- CUSIP
- 52635N103
- ISIN
- US52635N1037
- EIN
- 84-4867570
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Evert B. Schimmelpennink | President, CEO and Secretary, Director | 77,289 |
| Daniel R. Chevallard | Chief Financial Officer | 12,886 |
| Marc Odrich | Chief Medical Officer | 99,599 |
| Shawn Olsson | Chief Commercial Officer | 4,733 |
| Shelley B. Thunen | Director | – |
| Capital Healthcare Fund LP RA | Director | – |
| Ra Capital Management, L.P. | Director | – |
| Zachary Scheiner | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | 164,729 |
| Frederic Guerard | Director | – |
| Jeffrey P. George | Director | 5,592 |
| Peter Kolchinsky | Director | – |
| Kimberlee C. Drapkin | Director | – |
| James W. McCollum | Director | 631,099 |
| Rajeev M. Shah | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 152 employees, none of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 22, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 22, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 19, 2024 | Name change | Name changed from Graphite Bio, Inc. to LENZ Therapeutics, Inc. |
| Dec 6, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 28, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 22, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |